Boston Scientific (BSX) Stock Drops Despite Market Gains: Important Facts to Note

Boston Scientific (BSX) closed the most recent trading day at $95.72, moving -1.97% from the previous trading session. This change lagged the S&P 500's daily gain of 0.16%. At the same time, the Dow added 0.17%, and the tech-heavy Nasdaq gained 0.26%. Prior to today's trading, shares of the medical device manufacturer had gained 5.47% outpaced the Medical sector's gain of 2.84% and the S&P 500's gain of 1.89%.Investors will be eagerly watching for the performance of Boston Scientific in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on February 4, 2026. The company is expected to report EPS of $0.78, up 11.43% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $5.27 billion, up 15.44% from the prior-year quarter. For the full year, the Zacks Consensus Estimates are projecting earnings of $3.04 per share and revenue of $20.06 billion, which would represent changes of +21.12% and 0%, respectively, from the prior year. It's also important for investors to be aware of any recent modifications to analyst estimates for Boston Scientific. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.08% higher. Boston Scientific presently features a Zacks Rank of #2 (Buy). Valuation is also important, so investors should note that Boston Scientific has a Forward P/E ratio of 28.28 right now. For comparison, its industry has an average Forward P/E of 20.42, which means Boston Scientific is trading at a premium to the group. It's also important to note that BSX currently trades at a PEG ratio of 1.73. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The average PEG ratio for the Medical - Products industry stood at 1.75 at the close of the market yesterday. The Medical - Products industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 153, positioning it in the bottom 38% of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. 5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the favorite stock to gain +100% or more in the months ahead. They includeStock #1: A Disruptive Force with Notable Growth and ResilienceStock #2: Bullish Signs Signaling to Buy the DipStock #3: One of the Most Compelling Investments in the MarketStock #4: Leader In a Red-Hot Industry Poised for GrowthStock #5: Modern Omni-Channel Platform Coiled to SpringMost of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. While not all picks can be winners, previous recommendations have soared +171%, +209% and +232%.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks